HMG co-reductase inhibitor
US5916595A · kind A · utility
26Cited by
12References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 12, 1997 |
| Grant date | Jun 29, 1999 |
| Priority date | — |
| Expiry date | Dec 12, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A controlled release dosage formulation is described which is based on a combination of: PA1 (a) a compressed tablet core which contains an alkyl ester of a hydroxy substituted naphthalene derivative a pharmaceutically acceptable, water swellable polymer and an osmotic agent; and PA1 (b) an outer coating layer which completely covers the osmotic core and comprises a pH sensitive coating agent and a water insoluble polymer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.